Company Overview and News

0
Acquisitions Aid Revenue Growth at Ensign Group (ENSG)

2018-07-11 zacks
The Ensign Group, Inc. (ENSG - Free Report) boasts a strong inorganic growth story, with more than 234 acquisitions made over 18 years. Its historical growth has been mainly driven by its expertise in acquiring real estate or leasing post-acute care operations and transforming those into market leaders. With each acquisition, the company had sharpened its expertise, both clinically and financially.
LMT PRAH LPNT ENSG GEN

9
ENSG / Ensign Group, Inc. (The) - Stock Institutional Ownership and Shareholders - Fintel.io

2018-07-10 fintel.io
Ensign Group, Inc. (The) (NASDAQ:ENSG) has 195 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 51,117,102 shares. Largest shareholders include Wasatch Advisors Inc, BlackRock Inc., Vanguard Group Inc, BlackRock Fund Advisors, Dimensional Fund Advisors Lp, Price T Rowe Associates Inc /md/, Keeley Asset Management Corp, Lsv Asset Management, State Street Corp, and BlackRock Institutional Trust Company, N.
STT BLK STT.PRC STT.PRE ENSG STT.PRD ELVT LULU STT.PRG

0
ENSG / Ensign Group, Inc. (The) / VANGUARD GROUP INC - null (Passive Investment)

2018-07-10 sec.gov
ensigngroupincthe.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
ENSG

0
ENSG / Ensign Group, Inc. (The) / VANGUARD GROUP INC - null (Passive Investment)

2018-07-10 sec.gov
ensigngroupincthe.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
ENSG

0
National Health Investors: Better Choice Than Omega Or Ventas?

2018-07-09 seekingalpha
Too much emphasis has been placed on future demand for senior housing, with less emphasis on the dynamics of supply and cost pressure on tenants.
ENSG GEN NHI

1
Ensign Boosts Skilled Nursing Facility With McCall Buyout

2018-07-04 zacks
The Ensign Group, Inc. (ENSG - Free Report) , has acquired the real estate and operations of McCall Rehabilitation and Care Center, a 40-bed skilled nursing facility located in McCall, ID. The acquisition came into effect on Jul 1, 2018.
BLT BHP GTS BHPBF ENSG BBL WCG BHP HUM BHPLF

8
The Zacks Analyst Blog Highlights: ABIOMED, Lululemon, Insperity, DMC and Ensign

2018-07-03 zacks
Chicago, IL –July 3, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include ABIOMED, Inc. (ABMD - Free Report) , Lululemon Athletica Inc. (LULU - Free Report) , Insperity, Inc. (NSP - Free Report) , DMC Global Inc.
ABX ENSG LULU NSP ABMD JOUT ABX

0
The Ensign Group Acquires Idaho Skilled Nursing Facility

2018-07-03 globenewswire
MISSION VIEJO, Calif., July 03, 2018 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (NASDAQ:ENSG), the parent company of the Ensign™ group of skilled nursing, rehabilitative care services, home health care, hospice care and assisted living companies, announced today that it acquired the real estate and operations of McCall Rehabilitation and Care Center, a 40-bed skilled nursing facility located in McCall, Idaho.
ENSG

38
New Strong Buy Stocks for July 2nd

2018-07-02 zacks
Elevate Credit, Inc. (ELVT - Free Report) : This company that provides online credit solutions has seen the Zacks Consensus Estimate for its current year earnings increasing 4% over the last 60 days.
WFC WFCNP WFC.WS ENSG ELVT WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN SEDG WFC.PRY WFC.PRX WFC.PRW WFC.PRV

77
5 Top Stocks to Buy for the Second Half of 2018

2018-07-02 zacks
The first of half of this year was mostly topsy-turvy, with major indices failing to make a big move. While a group of investors showed a lot of optimism on corporate earnings and upbeat labor data, many fear that the Fed’s stance to raise interest rate hikes faster might derail the market’s upward journey. Intensifying trade tensions between the United States and China may also force the equity market to take a dive after years of growth.
JBK GS.PRICL GSC ENSG TFG GS.PRB GS.PRA GSJ GS.PRJ GS.PRI GS GLSSP GS.PRD GS.PRC LULU NSP ABMD GJS GS.PRN GS.PRK

8
5 Knockout Stocks to Play the World Cup Fever

2018-06-29 investorplace
FIFA World Cup 2018 will enter the knockout stage today. As the top 16 teams fight it out for the coveted trophy, soccer fans will be closely watching a host of the stars, who will be contending for the five big awards — Golden Ball, Golden Boot, Golden Glove and the FIFA Fair Play Trophy.
ENSG AMED CRMT

3
New Strong Buy Stocks for June 28th

2018-06-28 zacks
The Ensign Group, Inc. (ENSG - Free Report) : This company that provides health care services has seen the Zacks Consensus Estimate for its current year earnings increasing 1.1% over the last 60 days.
MT JEC GM.WS.A ENSG GM.WS.B GM.WS.C GM GM.WSB MT KFY

13
5 Knockout Stocks to Play the World Cup Fever Pitch

2018-06-28 zacks
FIFA World Cup 2018 will enter the knockout stage today. As the top 16 teams fight it out for the coveted trophy, soccer fans will be closely watching a host of the stars, who will be contending for the five big awards — Golden Ball, Golden Boot, Golden Glove and the FIFA Fair Play Trophy.
NOG ENSG AMED KFY CRMT

14
New Strong Buy Stocks for June 26th

2018-06-26 zacks
ConocoPhillips (COP - Free Report) : This company that explores for, produces, transports, and markets crude oil has seen the Zacks Consensus Estimate for its current year earnings increasing 20.2% over the last 60 days.
COP ENSG PGR ZAGG DLPH

13
New Strong Buy Stocks for June 22nd

2018-06-22 zacks
Delphi Technologies PLC (DLPH - Free Report) : This company that design, development, and manufacture of integrated powertrain technologies has seen the Zacks Consensus Estimate for its current year earnings increasing 2.9% over the last 60 days.
NOG TM ENSG 7203 TYT TOYOF DLPH MEOH

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

8h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

9h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 29358P101